CGTLive Interview: New Frontiers in Allogeneic Cell Therapy

By Karen Loudon / January 20, 2023
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and...
Read More

Cartherics granted first patent in China for multiple development candidates

By Karen Loudon / January 9, 2023
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment...
Read More

Cartherics to Present at Biotech Showcase™ 2023

By Karen Loudon / December 22, 2022
Cartherics to Present at Biotech Showcase™ 2023 Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program...
Read More

Message from the CEO – December 2022

By Karen Loudon / December 14, 2022
This year has been an exciting and productive one for Cartherics. We opened our new and impressive research and development...
Read More

Breaking the Mould: Building a Research-Based Biotech Company in Australia from Scratch

By Karen Loudon / December 7, 2022
Ian Nisbet and Alan Trounson, AO Australia is a very challenging environment for early-stage biotechnology companies. Risk capital is hard...
Read More

Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma

By Karen Loudon / November 8, 2022
Melbourne, Victoria, Australia - 08 November 2022 The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced...
Read More

Cartherics is ‘Frocking Up’ this month in support of ovarian cancer research

By Karen Loudon / October 17, 2022
Cartherics is delighted to be participating in Frocktober – Australia’s most fashionable month-long fundraiser to raise awareness and funds for...
Read More

Cartherics unveils new $4M lab to develop cancer immunotherapy treatments in Victoria

By Karen Loudon / October 13, 2022
MELBOURNE, Australia, 13 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has...
Read More

Cartherics granted first US patent for multiple development candidates

By Karen Loudon / October 6, 2022
Melbourne, Australia, 06 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced...
Read More

Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers

By Karen Loudon / September 30, 2022
MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together...
Read More

3 Cheers for a Cartherics Board Member

By Karen Loudon / June 16, 2022
Bryan Williams ranked among the world’s most prominent scientists By Leigh Dayton, 16 June 2022 Cartherics is delighted to announce...
Read More

She’s an Adventurer, Advocate, Author and a Cancer Survivor

By Karen Loudon / June 9, 2022
Now Heather Hawkins is a member of the Cartherics Board By Leigh Dayton  9 June 2022 It’s official. As of...
Read More

Presentation at the Locust Walk Stem Cell Tx Conference

By carth_admin / April 8, 2022
Dr Ian Nisbet Chief Operating Officer Held in partnership with Harvard Stem Cell Institute, this virtual one-day investor and partner...
Read More

Congratulations to Cartherics CEO

By carth_admin / April 1, 2022
Alan Trounson is ranked among the world’s most prominent scientists
Read More

Cartherics CEO discusses the importance of industry-academic collaboration with new partner

By carth_admin / March 30, 2022
In the following interview with ARMI Alan Trounson discusses the importance and challenges of translation
Read More
1 2 3 9